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Abstract: Although anti-TNF drugs have changed the clinical course of rheumatoid arthritis 
(RA), survival rates and resistance-to-therapy data confirm that about 30% of RA patients fail 
to respond. The aim of this study was to evaluate the correlations between the development of 
antidrug antibodies, specific IgG
4
 antibodies against TNF inhibitors, and resistance to therapy in 
RA patients. This retrospective study involved 129 patients with established RA naïve to biologi-
cal agents (98 females and 32 males, mean age 56.7±12.3 years, disease duration 6.3±1.2 years, 
baseline Disease Activity Score [DAS]-28 3.2–5.6) who received treatment with anti-TNF 
agents after the failure of conventional disease-modifying antirheumatic drugs (32 received inf-
liximab [IFX], 58 etanercept [ETN], and 39 adalimumab [ADA]). After 6 months of treatment, 
the patients were classified as being in remission (DAS28 ,2.6), having low disease activity 
(LDA; DAS28 2.6–3.2), or not responding (NR: DAS28 .3.2). The patients were also tested for 
serum antidrug antibodies and IgG
4
 antibodies against TNF inhibitors. After 24 weeks of treat-
ment, 38% of the ETN-treated patients and 28% of those treated with ADA had injection-site 
reactions; the rate of systemic reactions in the IFX group was 25%. The differences among the 
three groups were not statistically significant (P=0.382; ETN versus ADA P=0.319). The percent-
ages of patients with adverse events stratified by drug response were: LDA 8% and NR 18% in 
the ADA group; in remission 3%, LDA 22%, and NR 10% in the ETN group; and LDA 6% and 
NR 16% in the IFX group (P=0.051). The percentages of patients with antidrug antibodies were: 
ADA 33.3%, ETN 11.5%, and IFX 10.3% (P=0.025; ADA versus ETN P=0.015). The percent-
ages of patients with IgG
4
 antibodies were: ADA 6%, ETN 13%, and IFX 26% (P=0.017; ADA 
versus ETN P=0.437). Associations between antidrug antibodies, specific IgG
4
 antibodies, and 
adverse reactions were not significant for any of the three drugs. IgG
4
 levels were higher in the 
ADA group than in the other two groups, and higher in the patients with worse DAS28 (NR) and 
in those experiencing adverse events. These data suggest a possible association between IgG
4
 
levels and worse DAS28 (r2=5.8%, P=0.011). The presence of specific IgG
4
 antibodies against 
TNF blockers in patients with RA might affect the drugs’ activity. Patients with injection-site 
reactions and IgG
4
 against ETN may show a decreased response.
Keywords: antidrug antibodies, TNF-blocking agents, IgG
4
 antibodies
Introduction
Over the last 20 years, biological therapies (especially TNF inhibitors) have revolution-
ized the management of chronic inflammatory diseases, including rheumatoid arthritis 
(RA). Disease management has been dominated by the three TNF inhibitors infliximab 
(IFX), adalimumab (ADA), and etanercept (ETN), but despite an acceptable response 
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rate of 60%–70%, a substantial proportion of patients fail 
to respond (primary failure) or experience significant side 
effects.1 Some questions have also arisen concerning the 
safety of TNF inhibitors, because they can trigger immuni-
zation, induce rare type I and III hypersensitivity, and cause 
acute and delayed reactions.
There have been many reports of reactions in patients 
receiving intravenous IFX, a chimeric IgG
1k
 anti-TNF agent,2 
and immunomediated side effects, such as cutaneous reac-
tions, have been encountered during therapy with subcutane-
ous anti-TNF drugs. One recent paper described injection-site 
reactions in 29.3% of patients treated with ETN.3 Adverse 
reactions to biological agents have been categorized into 
five types, including a complement-mediated reaction 
with immediate IgE or delayed IgG antibody formation.4 
The immunoglobulin IgG
4
 is an IgG subtype that has been 
described by some authors (particularly Parish in the 1970s)5 
as potentially causing transient sensitization that leads to 
signs and symptoms comparable with those induced by IgE-
mediated reactions; this was initially termed IgG short-term 
sensitizing by Parish, because upon passive transfer to normal 
skin, the sensitivity persists for only 2–4 hours. IgG
4
 differs 
from IgE insofar as it present in amounts that are large enough 
to be detected by agglutination or precipitation assays, and 
its sensitizing activity is not destroyed by heat or (in most 
cases) chemical reducing agents.4
All biological agents (whether of entirely human origin, 
chimeric, or “humanized”) can cause an immune response, 
leading to the formation of antidrug antibodies (ADAbs), 
which are also known as human antichimeric antibodies or 
human antihuman antibodies, depending on the nature of the 
drug. The generation of ADAbs is increasingly recognized 
as a mechanism explaining the failure of anti-TNF drugs in 
chronic inflammatory diseases. The lack of a clinical response 
in patients with ADAbs may be due to the formation of an 
immune complex between TNF inhibitors and ADAbs that 
suppresses the drug and restricts its therapeutic activity.1
The aim of this study was to evaluate the correlations 
between the development of ADAbs and specific IgG
4
 anti-
bodies against TNF inhibitors, adverse local and general 
hypersensitivity events, and resistance to therapy in RA 
patients.
Materials and methods
This retrospective study involved 129 patients with established 
RA naïve to biological agents (98 females and 32 males, 
mean age 56.7±12.3 years, disease duration 6.3±1.2 years, 
baseline Disease Activity Score [DAS]-28 scores 3.2–5.6) 
who received treatment with anti-TNF agents after the failure 
of conventional disease-modifying antirheumatic drugs: 32 
(24.8%) received IFX, 58 (44.9%) ETN, and 39 (30.3%) ADA. 
Table 1 shows their baseline characteristics.
After 6 months of treatment, the patients were classified as 
being in remission (DAS28 ,2.6), having low disease activity 
(LDA; DAS28 2.6–3.2), or not responding (NR; DAS28 .3.2). 
During the 24 weeks of treatment, we also evaluated injection-
site reactions in patients treated with ETN or ADA, and sys-
temic reactions in those treated with IFX.
The patients were tested for serum ADAbs with an anti-
TNFα-blocker enzyme-linked immunosorbent assay kit 
(Immundiagnostik, Milan, Italy) and IgG
4
 antibodies against 
TNF inhibitors (fluoroenzyme immunoassay kit for Immu-
noCap® 250; Phadia, Uppsala, Sweden). ADAb (Immun-
diagnostik) titers higher than 0.44 OD for ETN, 0.18 OD 
for ADA, and 0.27 for IFX were considered positive. IgG
4
 
antibodies against TNF inhibitors (ImmunoCap) higher than 
5.9 mg arbitrary unit/liter for ETA, 19.5 mg A/L for ADA, 
and 8.6 mg A/L for IFX were considered positive.
statistical analysis
Power calculation was performed on correlation coefficients 
considering Fisher’s Z-transformation, with an α-value 
of 0.05. For our simulation, we considered the following 
scenarios: a correlation coefficient ranging from 0.4 to 0.6 
and a lower 95% confidence limit of the correlation coeffi-
cient (null correlation) ranging from 0.05 to 0.1. In the more 
conservative scenario (r
sp
 =0.4 and null correlation of 0.1), 
we calculated that more than 90 subjects inclusive of up 
to 10% of missing values may be considered sufficient to 
achieve a nominal power over 90% (Figure S1).
Table 1 characteristics of patients at baseline
Infliximab 
32 patients
Adalimumab 
39 patients
Etanercept 
58 patients
age (years) 52.3±12.2 53.6±11.8 54.5±12.9
Disease duration 5.3±2.8 5.5±3.1 5.8±2.9
rheumatoid  
factor positivity
76% 78% 75%
aPca positivity 81% 79% 78%
esr, mm 54.3±8.4 55.7±7.2 53.5±6.7
crP, mg/dl 3.2±1.7 3.4±1.5 3.7±1.4
Das28 5.46±2.1 5.43±1.9 5.38±1.8
corticosteroids  
dose, mg/day
6.1±1.2 6.4±1.1 6.3±1.2
Methotrexate  
dose, mg/week
12.5±2.2 12.1±2.1 11.9±2.4
Abbreviations: aPca, anti-citrullinated peptide/protein antibody; esr, erythrocyte-
sedimentation rate; crP, c-reactive protein; Das, Disease activity score.
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statistics revised
Continuous variables were expressed as means ± standard 
deviation and categorical variables were described by 
percentages. The χ2 test was used to compare categorical vari-
ables among groups, and the Pearson correlation coefficient 
was used to investigate for relations between quantitative 
variables. An α-value of 0.05 was considered statistically 
significant, and all statistical tests were two-tailed. IgG
4
 levels 
were considered positive if superior to the following cutoff 
values: ETN 5.9, ADA 19.25, and IFX 8.6. ADAb levels 
were considered positive if superior to the following cutoff 
values: ETN 0.446, ADA 0.187, and IFX 0.275. Analyses 
were performed using Minitab16 software.
Results
After 24 weeks of treatment, 38% of the ETN-treated patients 
and 28% of those treated with ADA had injection-site 
reactions; the rate of systemic reactions in the IFX group 
was 25%. The differences were not statistically significant 
(P=0.382; ETN vs ADA P=0.319).
The percentages of patients with adverse events strati-
fied by drug response were: LDA 8% and NR 18% in the 
ADA group; remission 3%, LDA 22%, and NR 10% in 
the ETN group; and LDA 6% and NR 16% in the IFX 
group (P=0.051). The percentages of patients with ADAbs 
were: ADA 33.3%, ETN 11.5%, and IFX 10.3% (P=0.025; 
ADA vs ETN P=0.015). The percentages of patients with 
IgG
4
 antibodies were: ADA 6%, ETN 13%, and IFX 26% 
(P=0.017; ADA vs ETN P=0.437). Associations between 
ADAbs, specific IgG
4
 antibodies and adverse reactions were 
not significant for any of the three drugs.
A scatter plot showed a positive correlation between 
IgG
4
 levels and worse DAS28, (0.241, r2=5.8%; P=0.011; 
Figure 1). IgG
4
 quantities were higher in the ADA group 
than in the other two groups (Figure 2), but the correlation 
with DAS28 was only significant for the ETN group, (ADA 
0.287, P=0.094; ETN 0.299, P=0.039; IFX 0.314, P=0.097). 
The correlation between ETN and DAS28 was consistent 
with the higher percentage of ETN patients positive for IgG
4
 
(shown earlier) with respect to the ADA patients. There 
was a positive correlation between IgG
4
 levels (regardless 
of the drug group) in patients experiencing adverse events 
(Figure 3, red line and dots; subjects having experienced 
adverse events correlating with DAS28 value =0.578, 
r2=33.5%; P=0.000).
Discussion
Our results suggest that IgG
4
 may play a role in the adverse 
reactions and therapeutic response to biological agents 
of patients with RA. The role of anti-ADA IgG
4
 was first 
detected by means of an immunoassay in 271 consecutive 
RA patients during 3 years of treatment: anti-ADA antibodies 
were detectable in 32%, and specific IgG
4
 antibodies in 29%. 
Although IgG
4
 is often considered to be harmless due to its 
lack of an effector function, the neutralization of ADA by 
specific IgG
4
 antibodies leads to a reduced clinical response.6 
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Figure 1 Scatter plot of specific IgG4 antibodies versus Das28.
Abbreviation: Das, Disease activity score.
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Figure 2 igg4 specific antibodies against three different TNF blocking agents and 
Das28.
Abbreviation: Das, Disease activity score.
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Figure 3 correlation between igg4 specific antibodies, adverse effects and DAS28.
Abbreviations: Das, Disease activity score; ra, rheumatoid arthrirtis.
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In our 24-week study, we detected ADAbs in 33.3% of our 
ADA patients and IgG
4
 in only 6%.
Approximately 4% of the total IgG in the serum of Cau-
casian adults is IgG
4
,7 which is considered an odd antibody 
insofar that it is the only IgG unable to activate complement 
and has a low affinity for Fcγ receptors.8,9 Furthermore, it 
is able to exchange half-molecules in vivo, thus leading to 
bispecific antibodies that do not cross-link and the consequent 
formation of small immune complexes.10,11 Because of its 
limited ability to trigger immunological effector functions 
and its tendency to form small immune complexes, it is 
thought that IgG
4
 has less effect on the clearance of antigens 
and plays a limited role in inflammation.
Although the percentage of serum IgG
4
 is generally low, 
antigen-specific IgG
4
 has been described as the main isotype 
produced in some immune responses. As early as the 1970s, it 
was shown that chronic antigen exposure to grass pollen and 
bee venom led to the predominant formation of IgG
4
,12 and 
increased allergen-specific IgG
4
 is associated with a benefi-
cial response to specific allergen immunotherapy in allergic 
patients.13,14 Chronic treatment with biological agents, such as 
factor VIII, IFNβ, or therapeutic monoclonal antibodies can 
be considered long-term exposure to protein antigens. There 
have been frequent reports of the formation of IgG antibodies 
against biological agents, some of which have been found to 
produce IgG
4
. Prolonged exposure to IFNβ can also lead to 
the development of IgG
4
 antibodies in patients with multiple 
sclerosis,15 but although it has been shown that therapeutic 
monoclonal antibodies can give rise to the formation of IgG
4
, 
there is lack of long-term measurements.16,17 The observation 
that the proportion of IgG
4
 antibodies may diminish over 
time is somewhat unusual, and differs from what has been 
described in the various allergens.18
Our results showed more injection-site reactions in the 
ETN group than in the ADA group (38% vs 28%), and the 
presence of anti-ETN IgG
4
 in 13% of the patients. Although 
it is not yet known what factors induce class switching to 
IgG
4
, it can be speculated that the immunological context 
of the patients and/or the intensity of treatment (dosing and 
frequency) may play a role. One of the reasons for the dif-
ference in IgG
4
 responses between ADA-treated and aller-
gic patients may be that the former received 40 mg every 
2 weeks, whereas the patients receiving allergen-specific 
immunotherapy received 20 µg of allergen twice a week. 
The frequency of treatment could also explain the increase 
in anti-ETN IgG
4
.
Our findings indicate a correlation between adverse drug 
reactions and a poor response, and suggest that anti-ETN 
IgG
4
 may have a decreased response to ETN therapy. Other 
studies have shown that the formation of anti-ADA antibodies 
is related to lower functional drug levels and a diminished 
clinical response.19,20 A large proportion of these antibodies 
are IgG
4
 antibodies, which suggests IgG
4
 is not simply an 
innocent bystander in this case.21 Although IgG
4
 antibodies 
cannot activate complement and have a low affinity for Fc 
receptors, they may still be able to compete with drug-
induced TNFα binding to drugs, thus leading to a clinical 
nonresponse.
We detected anti-ADA antibodies more frequently than 
anti-ETN antibodies (33% vs 11.5%), whereas the rate of 
detection of IgG
4
 anti-ETN was 13%, which may predict a 
lower response to ETN therapy in patients with injection-site 
reactions. One limitation of this study is that it did not mea-
sure the serum levels of the three drugs. Our study confirms 
that patients with injection-site reactions and anti-ETN IgG
4
 
may not respond to ETN therapy.
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